- Home
- PRM vs GLPG Comparison
PRM vs GLPG Comparison
Compare PRM & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRM
- GLPG
- Stock Information
- Founded
- PRM 2018
- GLPG 1999
- Country
- PRM United States
- GLPG Belgium
- Employees
- PRM N/A
- GLPG N/A
- Industry
- PRM Newspapers/Magazines
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- PRM Consumer Discretionary
- GLPG Health Care
- Exchange
- PRM Nasdaq
- GLPG Nasdaq
- Market Cap
- PRM N/A
- GLPG 1.8B
- IPO Year
- PRM N/A
- GLPG 2005
- Fundamental
- Price
- PRM $10.41
- GLPG $24.60
- Analyst Decision
- PRM Strong Buy
- GLPG Sell
- Analyst Count
- PRM 2
- GLPG 5
- Target Price
- PRM $16.00
- GLPG $26.75
- AVG Volume (30 Days)
- PRM 1.3M
- GLPG 159.8K
- Earning Date
- PRM 05-08-2025
- GLPG 04-23-2025
- Dividend Yield
- PRM N/A
- GLPG N/A
- EPS Growth
- PRM N/A
- GLPG N/A
- EPS
- PRM N/A
- GLPG 1.16
- Revenue
- PRM $560,968,000.00
- GLPG $285,380,474.00
- Revenue This Year
- PRM N/A
- GLPG $0.08
- Revenue Next Year
- PRM $5.01
- GLPG $0.23
- P/E Ratio
- PRM N/A
- GLPG $21.87
- Revenue Growth
- PRM 74.16
- GLPG 14.99
- 52 Week Low
- PRM $6.84
- GLPG $22.36
- 52 Week High
- PRM $14.44
- GLPG $32.57
- Technical
- Relative Strength Index (RSI)
- PRM 54.52
- GLPG 46.62
- Support Level
- PRM $8.97
- GLPG $25.07
- Resistance Level
- PRM $10.77
- GLPG $25.72
- Average True Range (ATR)
- PRM 0.37
- GLPG 0.50
- MACD
- PRM 0.25
- GLPG -0.12
- Stochastic Oscillator
- PRM 75.40
- GLPG 20.10
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.